Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combi
Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation – GB1275 granted Orphan Drug Designation for...
top of page
A L T I T U D E
Life Science Ventures
Companies in the News
Nov 5, 2019
Effector Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (EFT226) in Patient
Program addresses aggressive cancers with RTK (HER2, ERBB3, FGFR1, FGFR2) and KRAS mutations SAN DIEGO, November 5, 2019 — eFFECTOR...
Nov 5, 2019
Gritstone Oncology Announces Data on Novel Shared Tumor-Specific Neoantigens Identified by its EDGE
EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company...
bottom of page